Autoantibody detection method, method for testing possibility of autoimmune disease contraction, autoantibody detection reagent, and autoimmune disease test reagent

Patent metadata

Field	Value
Publication number	US-9778257-B2
Application number	US-201414905621-A
Country	US
Kind code	B2
Filing date	Jan 17, 2014
Priority date	Jul 17, 2013
Publication date	Oct 3, 2017
Grant date	Oct 3, 2017

Abstract

The present invention provides an autoantibody detection method that can detect an autoantibody causing an autoimmune disease with high accuracy. The autoantibody detection method of the present invention includes the steps of; causing a sample and an antigen reagent comprising a denatured protein presented by an MHC class II molecule to come into contact with each other; and detecting a complex of an autoantibody in the sample and the denatured protein in the antigen reagent. By detecting a complex of the autoantibody and the denatured protein in a biological specimen isolated from a subject according to this detection method, it is possible to test the possibility of the autoimmune disease in the subject from the detection result.

First claim

The invention claimed is:

1. A detection method for detecting an autoantibody, the detection method comprising the steps of:
causing a sample and an antigen reagent comprising a denatured protein presented by an MHC class II molecule to come into contact with each other; and
detecting a complex of an autoantibody in the sample and the denatured protein in the antigen reagent,
wherein the denatured protein is a misfolded protein resulting from denaturation of folding in a correctly folded protein.

2. The detection method according to claim 1 , wherein
the denatured protein is a denatured protein presented by an MHC class II molecule, obtained by introducing a gene encoding a correctly folded protein into an MHC class II molecule expression system cell.

3. The detection method according to claim 1 , wherein
the denatured protein is a protein resulting from denaturation of a correctly folded protein involved in an autoimmune disease.

4. The detection method according to claim 1 , wherein
the denatured protein is a protein resulting from denaturation of at least one selected from the group consisting of an IgG heavy chain, thyroglobulin, β2-glycoprotein I, and a thyroid-stimulating hormone receptor.

5. The detection method according to claim 1 , wherein
the MHC class II molecule is at least one selected from the group consisting of HLA-DR, HLA-DP, and HLA-DQ.

6. The detection method according to claim 1 , wherein
the MHC class II molecule is at least one selected from the group consisting of HLA-DR1, HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR5, HLA-DR6, HLA-DR7, HLA-DR8, HLA-DR13, HLA-DR14, HLA-DR15, HLA-DQ3, HLA-DQ6, HLA-DQ8, HLA-DP4, and HLA-DP5.

7. The detection method according to claim 1 , wherein
combination of the MHC class II molecule and the denatured protein is at least one selected from the group consisting of the following combinations (1) to (4):

(1) the MHC class II molecule is HLA-DR, and the denatured protein is a denatured protein resulting from denaturation of an IgG heavy chain;
(2) the MHC class II molecule is HLA-DR, and the denatured protein is a denatured protein resulting from denaturation of thyroglobulin;
(3) the MHC class II molecule is HLA-DR, and the denatured protein is a denatured protein resulting from denaturation of β2-glycoprotein I; and
(4) the MHC class II molecule is HLA-DP, and the denatured protein is a denatured protein resulting from denaturation of a thyroid-stimulating hormone receptor.

8. A test method for testing a possibility of an autoimmune disease, wherein a sample is a biological specimen isolated from a subject, the test method comprising the steps of:
detecting a complex of an autoantibody in the sample and a denatured protein presented by an MHC class II molecule by the detection method according to claim 1 ; and
evaluating the possibility of the autoimmune disease from the result of detecting the complex in the detection step,
wherein, in the evaluation step, a measured value of the amount of complex formation obtained in the measurement step is compared with a reference value, and it is determined that the subject has a possibility of the autoimmune disease when the measured value is higher than the reference value, and
the reference value is the amount of complex formation in a biological specimen isolated from a healthy donor.

9. The test method according to claim 8 , wherein
the detection step is the step of measuring the amount of complex formation.

10. An autoantibody detection reagent for use in the detection method according to claim 1 , the autoantibody detection reagent comprising:
a denatured protein presented by an MHC class II molecule, and
the method comprising the step of preparing an MHC class II molecule presenting a denatured protein resulting from denaturation of a correctly folded protein by introducing a gene encoding the correctly folded protein into an MHC class II molecule expression system cell.

11. A screening method for an antigen protein against an autoantibody relevant to an autoimmune disease, wherein a sample is a biological specimen isolated from a subject affected with an autoimmune disease, the screening method comprising the steps of:
detecting a complex of an autoantibody in the sample and a denatured protein presented by an MHC class II molecule by the detection method according to claim 1 ; and
determining the denatured protein that has formed the complex with the autoantibody as an antigen protein against an autoantibody relevant to the autoimmune disease.

Assignees

• Univ Osaka

Inventors

• Arase Hisashi
• Tanimura Kenji
• Jin Hui
• ARASE Noriko

Classifications

• G01N33/56977

  HLA or MHC typing · CPC title

• G01N33/564 Primary

  for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9} · CPC title